Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Non-small cell lung cancer (NSCLC) in adult patients whose tumours have PD-L1 expression on ? 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations, monotherapy for adjuvant treatment following resection and platinum-based chemotherapy, Stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition)
Last updated:
March 14, 2023
Status:
Concluded without agreement
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Advanced or metastatic breast cancer, Hormone receptor-positive, HER2-negative, PIK3CA mutated, after disease progression following an endocrine-based regimen, in postmenopausal women and men (In combination with fulvestrant)
Last updated:
March 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Ultragenyx Canada Inc.
Indication:
Long-Chain Fatty Acid Oxidation Disorders
Last updated:
March 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Asthma
Last updated:
March 10, 2023
Status:
Concluded with an LOI
Manufacturer:
Tanvex BioPharma USA, Inc.
Indication:
Neutropenia in various indications (Prevention or treatment)
Last updated:
March 10, 2023
Status:
Negotiations were not pursued
Manufacturer:
AbbVie Corporation
Indication:
Diabetic Macular Edema
Last updated:
March 9, 2023
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors, in adult patients
Last updated:
March 9, 2023
Trodelvy (sacituzumab govitecan)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Triple-negative breast cancer (mTNBC), unresectable locally advanced or metastatic, in adult patients who have received two or more prior therapies, at least one of them for metastatic disease
Last updated:
March 9, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer in adult patients, whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.
Last updated:
March 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer in adult patients, whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.
Last updated:
March 8, 2023